Plasma cell myeloma

Hematol Oncol Clin North Am. 2009 Aug;23(4):709-27. doi: 10.1016/j.hoc.2009.04.012.

Abstract

Plasma cell myeloma is a heterogenous disease with variable clinical presentation and outcome. The prognosis is largely determined by tumor biology. Newer therapeutic agents are rapidly changing the survival outlook of myeloma patients.

Publication types

  • Review

MeSH terms

  • Cyclin D1 / genetics
  • Flow Cytometry
  • Histone-Lysine N-Methyltransferase / genetics
  • Humans
  • Immunoglobulin Heavy Chains / genetics
  • Immunophenotyping
  • Multiple Myeloma / diagnosis*
  • Multiple Myeloma / genetics*
  • Multiple Myeloma / immunology
  • Prognosis
  • Receptor, Fibroblast Growth Factor, Type 3 / genetics
  • Repressor Proteins / genetics
  • Translocation, Genetic

Substances

  • CCND1 protein, human
  • Immunoglobulin Heavy Chains
  • Repressor Proteins
  • Cyclin D1
  • Histone-Lysine N-Methyltransferase
  • NSD2 protein, human
  • FGFR3 protein, human
  • Receptor, Fibroblast Growth Factor, Type 3